Can investors be disappointed by licensing deals with nine-figure up-front payments? In the case of GlaxoSmithKline PLC’s worldwide (ex-Japan) co-development and co-promotion pact with Actelion Pharmaceuticals Ltd. for the Phase III orexin receptor antagonist almorexant for insomnia and other indications the answer is yes, but there was no unanimity of opinion. [See Deal]
In mid-July GSK fronted CHF 150 million ($148 million) for almorexant and pledged an additional CHF 415 million in pre-commercial...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?